“We are here representing the field of the science of aging. And we think that this is a historical day for us, because we're going to offer something that will be paradigm changing.”
Nir Barzilai, professor at Albert Einstein School of Medicine and director of Institute for Aging Research, presents the current state of the groundbreaking TAME trial serving as a framework and data springboard for the whole longevity field, as well as the future plans for other TAME-like trials with other drugs with high potential for repurposing for aging. At the end he also answers questions about the trial itself and why it is designed the way it is, but also some frequently asked questions about Metformin, like its effect on muscle building with exercise, the ideal dosing, and others.
The original audio recording has been altered for the purpose of this podcast.
Music:
Candlepower by Chris Zabriskie is licensed under a Creative Commons Attribution 4.0 license. https://creativecommons.org/licenses/by/4.0/
Source: http://chriszabriskie.com/divider/
Artist: http://chriszabriskie.com/
I Knew a Guy by Kevin MacLeod is licensed under a Creative Commons Attribution 4.0 license. https://creativecommons.org/licenses/by/4.0/
Source: http://incompetech.com/music/royalty-free/index.html?isrc=USUAN1100199
Artist: http://incompetech.com/
Remarks: The length of this recording has been altered.
Nir Barzilai | Targeting Aging with Metformin